IMC-18F1
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Jul 1, 2006 → Nov 1, 2009
NCT ID
NCT00782002About IMC-18F1
IMC-18F1 is a phase 1 stage product being developed by Eli Lilly for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00782002. Target conditions include Advanced Solid Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00782002 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors